Cyclo Therapeutics (CYTH) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free CYTH Stock Alerts $1.41 +0.01 (+0.71%) (As of 05/14/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 2, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Cyclo Therapeutics (CYTH) with Buy RecommendationApril 23, 2024 | nasdaq.comAscendiant Capital Initiates Coverage of Cyclo Therapeutics (CYTH) with Buy RecommendationApril 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)April 10, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Cyclo Therapeutics StockMarch 19, 2024 | investorplace.comCYTH Stock Earnings: Cyclo Therapeutics Reported Results for Q4 2023March 18, 2024 | businesswire.comCyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 14, 2024 | finance.yahoo.comCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s DiseaseMarch 14, 2024 | businesswire.comCyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's DiseaseFebruary 2, 2024 | finance.yahoo.comCyclo Therapeutics, Inc. (CYTH)January 29, 2024 | markets.businessinsider.comCyclo Therapeutics Gets Notice Of Allowance For Patent Regarding Treatment Of Alzheimer's DiseaseJanuary 29, 2024 | finance.yahoo.comCyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark OfficeJanuary 3, 2024 | morningstar.comCyclo Therapeutics Inc CYTHDecember 28, 2023 | msn.comCytosorbents, Cyclo Therapeutics among healthcare moversDecember 18, 2023 | finance.yahoo.comCyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1December 14, 2023 | finance.yahoo.comRafael Holdings Reports First Quarter Fiscal 2024 Financial ResultsNovember 29, 2023 | businesswire.comAPPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied ...November 21, 2023 | finance.yahoo.comCyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024November 15, 2023 | msn.comCyclo Therapeutics reports Q3 resultsNovember 15, 2023 | finance.yahoo.comCyclo Therapeutics Reports Third Quarter 2023 Financial ResultsNovember 10, 2023 | seekingalpha.comWISH, REAL and PIXY among mid-day moversNovember 2, 2023 | finance.yahoo.comSeveral Insiders Invested In Cyclo Therapeutics Flagging Positive NewsOctober 30, 2023 | finance.yahoo.comRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial ResultsOctober 23, 2023 | finance.yahoo.comCyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 MillionOctober 5, 2023 | finance.yahoo.comCyclo Therapeutics to Present at 8th Annual Dawson James ConferenceSeptember 21, 2023 | tmcnet.comCYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to ShareholdersSeptember 21, 2023 | finance.yahoo.comCyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger AgreementAugust 15, 2023 | finance.yahoo.comCyclo Therapeutics Reports Second Quarter 2023 Financial ResultsAugust 3, 2023 | benzinga.comCyclo Therapeutics And This Other Penny Stock Insiders Are BuyingJune 12, 2023 | benzinga.comCyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer's DiseaseMay 22, 2023 | finance.yahoo.comPositive Signs As Multiple Insiders Buy Cyclo Therapeutics StockMay 15, 2023 | finance.yahoo.comCyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsMay 2, 2023 | finance.yahoo.comCyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)April 28, 2023 | benzinga.comCyclo Therapeutics Stock (NASDAQ:CYTH), Guidance and ForecastApril 21, 2023 | finance.yahoo.comCyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq RulesMarch 21, 2023 | msn.comCyclo Therapeutics's Return On Capital Employed InsightsMarch 20, 2023 | marketwatch.comCyclo Therapeutics in Talks About Possible CombinationMarch 20, 2023 | finance.yahoo.comCyclo Therapeutics Provides Business Update and Reports Full Year 2022 Financial ResultsMarch 15, 2023 | seekingalpha.comCYTH Cyclo Therapeutics, Inc.March 10, 2023 | benzinga.comCyclo Therapeutics Chief Operating Officer Awarded $44K Worth of Stock OptionsMarch 10, 2023 | benzinga.comCyclo Therapeutics Chief Regulatory Officer Awarded $44K Worth of Stock OptionsMarch 10, 2023 | benzinga.comCyclo Therapeutics Board Member Awarded $3K Worth of Stock OptionsJanuary 11, 2023 | barrons.comCyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol(R) Cyclo(TM) for the Treatment of Early Alzheimer's DiseaseJanuary 11, 2023 | finance.yahoo.comCyclo Therapeutics Provides Clinical Program Update and Highlights Recent AchievementsJanuary 10, 2023 | finance.yahoo.comCyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch EventJanuary 9, 2023 | benzinga.comCyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer's DiseaseJanuary 9, 2023 | finance.yahoo.comCyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s DiseaseJanuary 4, 2023 | finance.yahoo.comCyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesJanuary 4, 2023 | finance.yahoo.comCyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual MeetingDecember 30, 2022 | msn.comCyclo Therapeutics announces direct offering for up to $4.2MDecember 30, 2022 | finance.yahoo.comCyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules Get Cyclo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (Ad)The AI boom continues to snowball with no signs of slowing... Google CEO, Sundar Pichai, made waves during a recent call with analysts, reminding them that the search engine company has been “AI first” since 2016. Get the full story here. CYTH Media Mentions By Week CYTH Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTH News Sentiment▼1.440.56▲Average Medical News Sentiment CYTH News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTH Articles This Week▼20▲CYTH Articles Average Week Get Cyclo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INAB News DYAI News OKYO News QNCX News SABS News ACHL News TARA News INKT News SRZN News AVRO News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTH) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
